Julie is the Chief Executive Officer and Director at Zentalis. Prior to joining Zentalis, she served as the Chief Executive Officer and President of Harpoon Therapeutics, a publicly traded clinical stage oncology company, from November 2021, and a member of its Board of Directors from October 2018, until its acquisition by Merck Sharpe & Dohme in March of 2024. Julie previously served as Chief Operating Officer and Chief Financial Officer of ReCode Therapeutics, a privately held genetics medicine company. Prior to ReCode, she served as Chief Financial Officer and Chief Business Officer of Rainier Therapeutics, a privately held biopharmaceutical company focused on bladder cancer. Before Rainier, she was Chief Financial Officer and Chief Business Officer of Cascadian Therapeutics, a publicly traded oncology company acquired by Seattle Genetics in 2018. Prior to Cascadian, Julie served as Chief Financial Officer and Vice President of Finance and Operations of VLST Corporation, a privately held biotechnology company, and held various financial and strategic management positions at publicly traded biotechnology companies including Dendreon and Amgen. Julie is an independent director of Dynavax Technologies Corporation, Lantheus, and Seismic Therapeutic. Julie received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.

Ingmar is Chief Medical Officer of Zentalis. He brings two decades of hematology and oncology experience as a physician and scientist. Prior to joining Zentalis, Ingmar served as Chief Medical Officer of Trillium Therapeutics, a publicly traded clinical stage oncology company, through its acquisition by Pfizer in November 2021, after which he served in clinical development roles at Pfizer, most recently as Development Head, Hematologic Malignancies, Pfizer Global Product Development. Ingmar previously served as the Senior Vice President and Head of Clinical Development at Pieris Pharmaceuticals, a publicly traded clinical stage biotechnology company, where he built and led the clinical development organization. From 2013 through 2017, he led clinical development of several high priority oncology assets at Bayer Pharmaceuticals. Previously, Ingmar served as an attending hematologist and oncologist as well as a physician-scientist at the University Hospital of Dusseldorf in Germany and Albert Einstein College of Medicine in New York. Ingmar is a board member at Radiant Biotherapeutics, a biotechnology company advancing a proprietary biologics platform designed to treat diseases such as cancer and autoimmune diseases. Ingmar has authored over 50 publications in the field of hematology and oncology, including several lead authorships in high impact journals such as Nature Medicine, Blood and Leukemia. He received his M.D. and Ph.D. from the University of Lubeck in Germany.

Wendy is the Chief People Officer of Zentalis. She brings over two decades of biopharma experience, including senior roles in human resources and an extensive background in aligning talent with organizations’ overall vision and direction. She was previously Chief People Officer at Harpoon Therapeutics. Before Harpoon, she was VP, Head of People & Culture for IDbyDNA. Wendy previously served in roles of increasing responsibility at Gilead Sciences from 2003 to 2020, most recently as Vice President, Human Resources, and, earlier in her career, at Bio-Rad Laboratories. She received a B.S. in accounting and business/management from the University of California, Riverside, and completed the Global Fellow of Talent Management program at The Wharton School of the University of Pennsylvania.

James Bucher is Chief Legal Officer and Corporate Secretary at Zentalis Pharmaceuticals. Previously, Jim served as Chief Legal Officer at Harpoon Therapeutics, where he played a pivotal role in the company's $680 million acquisition by Merck in 2024. Before that, he served as Executive Vice President and General Counsel and Head of Human Resources at Eliem Therapeutics, where he was a key founding member of the leadership team responsible for all legal affairs and corporate strategy, including the execution of three private placements and the company's initial public offering. Prior to Eliem, Jim was Executive Vice President and General Counsel at Alder Biopharmaceuticals, where he supported launch preparations for Vyepti and subsequently played a leading role in the company's $2.4 billion acquisition by Lundbeck. Earlier in his career, he served as Vice President, Corporate Legal Affairs & Secretary at Exelixis, where he oversaw more than $1 billion in capital raising transactions. Prior to transitioning in-house, Jim was a Partner at Shearman & Sterling LLP (now known as A&O Shearman), where he advised companies on a wide range of corporate and securities matters. He received his JD with distinction from Emory University School of Law and his BA in Biology and Political Science from Colgate University.

Haibo is the Chief Business Officer of Zentalis. He brings over 15 years of biopharma business development, finance, and M&A transaction experience, having most recently served as Senior Vice President of Business Development at Harpoon Therapeutics. While at Harpoon, he played a pivotal role in managing the Company’s acquisition by Merck, which was completed in March 2024. Prior to Harpoon, he served as the Vice President of Business Development at Hummingbird Bioscience, where he was responsible for the company’s end-to-end business development activities. Prior to Hummingbird, Haibo was Director of Business Development at Amgen, where he played a major role in the Teneobio and Five Prime Therapeutics acquisitions, the oncology collaboration with BeiGene, and many clinical collaborations to advance Amgen’s oncology pipeline. He began his career as an M&A consultant at Deloitte, advising on transactions in healthcare and technology. Haibo holds an M.S. in Biotechnology from Johns Hopkins University, an MBA from Duke University, and a BBA from Tsinghua University.

Bob is Senior Vice President of Technical Operations and Head of CMC at Zentalis Pharmaceuticals. He brings over 30 years of international pharmaceutical and biopharmaceutical experience in the design, implementation and operation of global supply chains for both commercial and investigational products. Prior to joining Zentalis, Bob served as Senior Vice President, Manufacturing and Supply for Zavante Therapeutics (acquired by Nabrivia Therapeutics in 2018), a late clinical-stage pharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients. Previously, Bob served as Vice President, Manufacturing and Supply for Cadence Pharmaceuticals. During his tenure, he developed and implemented the outsourced supply strategy for OFIRMEV® (acetaminophen) focusing on supply security and speed to market. Prior to Cadence, Bob was Vice President, European Supply at Valeant Pharmaceuticals in Basel, Switzerland, where he oversaw the global manufacturing and supply at the Company’s four major factories. Over the course of his career, he has held several senior operations and engineering roles, including at GlaxoSmithKline in the US and UK. Bob received his MSc in Manufacturing from the University of Cambridge, England and BS in Environmental Engineering from Temple University. He is a registered Professional Engineer (P.E.) and is a contributing member of the International Society of Pharmaceutical Engineers (ISPE).

Henry Gu is Senior Vice President, Head of Intellectual Property at Zentalis Pharmaceuticals, bringing over two decades of experience in patent procurement, due diligence, strategic IP counseling, and litigation. Prior to joining Zentalis, Henry held increasingly senior roles at several biopharmaceutical companies, including Morphic Therapeutic, Akebia Therapeutics, ARIAD Pharmaceuticals, and Cubist Pharmaceuticals. At Akebia, Henry played a pivotal role in the company’s merger with Keryx Biopharmaceuticals and was a key legal partner in major strategic collaborations with Otsuka Pharmaceutical and Mitsubishi Tanabe Pharma. He also led multiple ANDA litigations related to Auryxia®, successfully negotiating favorable settlements with generic challengers to extend market exclusivity. While at ARIAD, Henry was responsible for securing global IP protections across commercial, clinical, and discovery-stage assets. He was part of the core team that executed the company’s $5.2 billion acquisition by Takeda Pharmaceuticals. At Cubist, he managed the global patent portfolio for Cubicin®, the company’s blockbuster antibiotic, through its acquisition by Merck for $10 billion in 2015. Earlier in his career, Henry was Counsel at WilmerHale, where he advised Fortune 100 biopharmaceutical companies on complex IP matters. He began his legal career in-house at Bristol-Myers Squibb, after starting in the industry as a medicinal chemist. He holds a J.D. from Rutgers University School of Law, an M.S. in Organic Chemistry from Ohio University, and a B.S. in Applied Chemistry from Shanghai Jiao Tong University.

Rajesh is the Head of Regulatory, Biometrics, and Medical Writing at Zentalis, bringing over two decades of leadership in advancing oncology and immuno-oncology therapies. A passionate regulatory strategist, Rajesh has successfully guided multiple innovative treatments through global approval by developing and executing high-impact regulatory pathways.  He has held senior roles at Bristol Myers Squibb, Sanofi, Seagen, and Dragonfly Therapeutics, where he built and led high-performing teams with a strong emphasis on mentorship and organizational growth.  Rajesh has also spearheaded key strategic partnerships with major pharmaceutical companies, including Gilead, BMS, Merck, and AbbVie. While at Seagen, he played a pivotal role in establishing several successful collaborations, notably a global in-licensing and co-development agreement for a key oncology asset.  Bringing deep expertise in regulatory strategy and biometrics, combined with a collaborative leadership style, Rajesh plays a key role in advancing the development and approval of new therapies.  He holds a Master of Science in Biotechnology and Genomics from Rutgers University and a Master of Science in Information Systems from Stevens Institute of Technology, with a specialization in digital strategy for life sciences. He earned his Bachelor of Engineering from Amravati University in India.

Vince joined Zentalis as Controller/Senior Director, Finance in September 2020 and was subsequently promoted to Executive Director, Finance and Controller in January 2021, Vice President, Finance, in February 2023 and Senior Vice President and Principal Accounting Officer in July 2024. Before joining the Company, Mr. Vultaggio held roles of various responsibilities at life science and technology companies. Mr. Vultaggio began his career at Ernst & Young LLP, where he was a Manager, Assurance Services from September 2004 through April 2011. Mr. Vultaggio received a B.A. in Accountancy and an M.A. in Accountancy and Financial Management from the University of San Diego in 2004.